Clinical Trials Logo

Chinese clinical trials

View clinical trials related to Chinese.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05071742 Recruiting - Clinical trials for Inflammatory Bowel Disease

Correlation of Genetic Susceptibility Genes to Inflammatory Bowel Disease in Chinese Han Population

CGSGIBDCHP
Start date: November 25, 2021
Phase:
Study type: Observational

The pathogenesis of IBD is still unclear, and the disease characteristics of IBD patients are affected by genetic susceptibility genes. Therefore, this study aims to explore the relationship between genetic susceptibility genes of IBD and the pathogenesis of IBD in Chinese Han population, in order to clarify the pathogenesis of IBD and provide basis for individualized treatment of IBD.

NCT ID: NCT04881292 Recruiting - Healthy Clinical Trials

RF Based QIMT & QAS Study on Chinese Adults

Start date: May 1, 2021
Phase:
Study type: Observational

This study intends to establish the normal reference values of carotid artery intima-media thickness and vascular elasticity of Chinese adults based on ultrasound radio frequency technology through a multi-center large-sample study, which provides important information for the risk prediction and prognosis evaluation of Chinese adults' cardiovascular disease.

NCT ID: NCT04190667 Recruiting - Clinical trials for Epithelial Ovarian Cancer

Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer

Start date: December 7, 2019
Phase:
Study type: Observational

The homologous recombination deficiency (HRD) status in Chinese population with epithelial ovarian cancer (EOC) is little known. This study would recruit 1300 Chinese EOC patients. A multi-panel testing of 36 genes would be given for these patients in their peripheral blood and tumor tissues. These 36 genes include: BRCA1, BRCA2, ABRAXAS1(FAM175A), ATM, ATR, BAP1, BARD1, BRIP1, C11ORF30(EMSY), CDK12, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCI, FANCL, MRE11A, NBN, PALB2, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54B, RAD54, MLH1, MSH2, MSH6, PMS2, EPCAM, STK11, TP53, CDH1. The study would select 150 patients with pathogenic or likely pathogenic mutations in BRCA1/2 and 150 patients without these mutations to further explore the HRD status. The HRD model is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients.

NCT ID: NCT04137718 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation

Start date: October 25, 2019
Phase:
Study type: Observational

Title: Multicenter observational study for clinicopathological characteristics and clinical efficacy of Chinese Non-Small Cell Lung Cancer (NSCLC) patients With Rare Driver Gene Mutation. Purpose: To observe the status of rare driver gene mutations in NSCLC patients and identify the subtypes of the mutations. By comparing and analyzing the relationship between different subtypes, clinicopathological features and clinical efficacy, to find out the effects on anti-tumor therapy and disease survival. And ultimately to promote the precise application of clinical specifications for new anti-tumor drugs. Study type: Observational